Lytix Q2 2023: ATLAS-IT-05 Fully Recruited - Redeye

Since our initiating coverage, Verrica presented promising results in BCC. Lytix has recruited the first planned 20 patients in its phase II study in lymphoma, while an additional 20 may be added after an interim analysis. Furthermore, a new investigator sponsored trial, ATLAS-IT-06, in neoadjuvant melanoma is planned to start in H1 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/941122/lytix-q2-2023-atlas-it-05-fully-recruited?utm_source=finwire&utm_medium=RSS